Invex Therapeutics (ASX:IXC) Retained Earnings: A$-20.40 Mil (As of Dec. 2025)


What is Invex Therapeutics Retained Earnings?

Invex Therapeutics ASX:IXC Retained Earnings is A$-20.40 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Invex Therapeutics's retained earnings for the quarter that ended in Dec. 2025 was A$-20.40 Mil.

Invex Therapeutics's quarterly retained earnings declined from Dec. 2024 (A$-19.58 Mil) to Jun. 2025 (A$-19.70 Mil) and declined from Jun. 2025 (A$-19.70 Mil) to Dec. 2025 (A$-20.40 Mil).

Invex Therapeutics's annual retained earnings declined from Jun. 2023 (A$-17.58 Mil) to Jun. 2024 (A$-19.22 Mil) and declined from Jun. 2024 (A$-19.22 Mil) to Jun. 2025 (A$-19.70 Mil).


Invex Therapeutics  (ASX:IXC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Invex Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Retained Earnings Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial -5.88 -9.83 -17.58 -19.22 -19.70

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.69 -19.22 -19.58 -19.70 -20.40

Invex Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-20.40 Mil mean?
Invex Therapeutics (ASX:IXC) has a Retained Earnings of A$-20.40 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Retained Earnings too high?
Invex Therapeutics' current Retained Earnings is A$-20.40 Mil.
How does Invex Therapeutics' Retained Earnings compare to VRTX and REGN?
Invex Therapeutics' Retained Earnings of A$-20.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Retained Earnings is A$-20.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Retained Earnings of A$-20.40 Mil. The current Retained Earnings is A$-20.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Retained Earnings is A$-20.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.